Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application

Stock News11-03

Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.

According to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137543318?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137543318","market":"sg","top_or_hot":-1,"title":"Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application","media":"Stock News","content":"<p>Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.</p>\n<p>According to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.</p>\n<p>According to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1137543318","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137543318","pubTimestamp":1762167854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0046":"生物疫苗","BK0028":"国家队","BK0057":"长吉图板块","000661":"长春高新","BK0239":"医药制造","BK0075":"新三板","BK0188":"融资融券"},"translate_title":"长春高新（000661.SZ）：GenSci134注射液获国内临床试验申请批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.\nAccording to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137543318","isCrawlerRequest":true}